2020
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
Diab A, Tykodi S, Daniels G, Maio M, Curti B, Lewis K, Jang S, Kalinka E, Puzanov I, Spira A, Cho D, Guan S, Puente E, Hoch U, Currie S, Nguyen T, Lin W, Tagliaferri M, Zalevsky J, Sznol M, Hurwitz M. 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. Journal For ImmunoTherapy Of Cancer 2020, 8: a256-a256. DOI: 10.1136/jitc-2020-sitc2020.0420.Peer-Reviewed Original ResearchBaseline tumor biopsiesMetastatic melanomaUntreated patientsPD-L1Clinical activityTumor biopsiesFDA breakthrough therapy designationGene expression profilesObjective response ratePD-L1 statusPhase 3 trialProgression-free survivalStage IV melanomaHigher ORRBiomarkers of responseNon-invasive biomarkersUnmet need existsBreakthrough therapy designationInstitutional review boardMedian PFSPrimary endpointDurable responsesComplete responseMore patientsOS rates
2019
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.
Hurwitz M, Cho D, Balar A, Curti B, Siefker-Radtke A, Sznol M, Kluger H, Bernatchez C, Fanton C, Iacucci E, Liu Y, Nguyen T, Overwijk W, Zalevsky J, Tagliaferri M, Hoch U, Diab A. Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. Journal Of Clinical Oncology 2019, 37: 2623-2623. DOI: 10.1200/jco.2019.37.15_suppl.2623.Peer-Reviewed Original ResearchPD-L1CD8 TILsResponse rateAnti-PD-1 therapyOngoing phase 1/2 studyPre-treatment tumor biopsiesTumor microenvironmentBaseline immune signaturesSurface PD-1Tumor immune signaturePhase 1/2 studyAdvanced solid tumorsUrothelial carcinoma patientsFavorable tumor microenvironmentBaseline immune phenotypeLow groupMedian valueRECIST 1.1Baseline demographicsImmune signaturesPrognostic factorsCarcinoma patientsPD-1Biomarker subgroupsImmune cells